Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be.

On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management.

Pfizer (NYSE:PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management. The stock has been trading about 63% below its all-time high.

Pfizer's stock price is way down, but the quarterly dividend it pays has risen for 16 consecutive years. At its beaten-down price, the stock offers an eye-popping 7.8% yield.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy now. Learn More »

If Pfizer continues its dividend-raising streak, investors who buy at recent prices could realize market-beating gains over the long run. Let's look a little closer at danuglipron, plus some bigger problems the company faces, to see if this stock could be a smart buy on the dip.

The end of Pfizer's oral GLP-1 program

The end of Pfizer's danuglipron program highlights just how risky the drug-development process can be. According to the company, it discontinued development after just one patient in a dose-optimization study experienced a liver injury that could have been caused by the experimental GLP-1 pill.

The danuglipron program's termination is disappointing, but it won't be the end of Pfizer's attempt to develop blockbuster weight-management drugs. The company has an oral glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist in phase 2 trials. Investors will probably hear more about this candidate, tentatively named PF-07976016, down the road.

Bigger problems

A disappointing outcome for a weight-management candidate isn't anywhere near the top of Pfizer's list of problems. Investors should be far more concerned with an upcoming loss of patent-protected market exclusivity for Eliquis. Sales of the oral blood thinner it markets in partnership with Bristol-Myers Squibb (NYSE:BMY) rose to $7.4 billion, or 11.6% of total revenue last year.

Eliquis is expected to lose patent-protected exclusivity in 2026, although generic competition in the U.S. market isn't expected to begin until 2028. Pfizer's second-largest revenue stream in 2024 could also start drying up soon. The Prevnar family of vaccines was responsible for over 10% of total sales last year. Prevnar 13 is expected to lose patent-protected exclusivity in the U.S. next year.

Vyndaqel has been a strong growth driver for Pfizer but probably not for much longer. This treatment prevents heart damage caused by transthyretin (TTR) amyloidosis and grew sales by 64% to reach $5.4 billion last year. Bridge Bio (NASDAQ:BBNG) and Alnylam (NASDAQ:ALNY) are now marketing competing treatments for the limited population of TTR amyloidosis patients with heart damage. In addition to competing treatments, Vyndaqel is expected to face generic competition in the U.S. in 2028.

Industrywide crisis ahead?

Drug developers need to communicate with regulators at the Food and Drug Administration (FDA) before, during, and after they run clinical trials for new drug candidates. In the U.S., many of those regulators recently lost their jobs.

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief medical officer.

Having the former CDER director on staff could be advantageous for Pfizer, but I'll be pleasantly surprised if the FDA completes new drug approvals at half the usual pace this year. According to reporting from STAT, more than a few FDA employees involved in the new drug approval process were among thousands recently fired from the agency.

A crippled FDA could be a huge problem for Pfizer and its peers who must constantly launch new drugs to overcome exclusivity losses for established products.

A buy on the dip

Many investors expect pharmaceutical industry lobbyists to prevent the Trump administration from rendering CDER incapable of reviewing new drug applications at its usual pace. They could be right, but I won't support an investment thesis that relies on industry lobbyists protecting a regulatory agency.

If you asked me a month ago, I would have called this stock a buy. In 2023, it earned FDA approval for nine new drugs and last year it reported over a dozen product approvals from the agency. With plenty of new products coming online, Pfizer had a good chance to overcome upcoming patent cliffs and maintain its dividend-raising streak